Digirad Corporation (DRAD)

Clau

Nuovo Utente
Registrato
10/11/99
Messaggi
5.115
Punti reazioni
139
Digirad Corporation (DRAD)




2.03

Sopra alle Ema
 
Anche qui acquisti importanti di insiderTicker Owner Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DRAD Gillman Charles M Director Jul 17 Buy 2.46 5,000 12,299 741,985 Jul 19 08:48 PM
DRAD Gillman Charles M Director Jul 18 Buy 2.45 5,000 12,239 746,985 Jul 19 08:48 PM
DRAD Gillman Charles M Director Jul 19 Buy 2.44 5,000 12,209 751,985 Jul 19 08:48 PM
DRAD Eberwein Jeffrey E. Director Jul 17 Buy 2.46 5,000 12,300 741,985 Jul 19 08:47 PM
DRAD Eberwein Jeffrey E. Director Jul 18 Buy 2.45 5,000 12,242 746,985 Jul 19 08:47 PM
DRAD Eberwein Jeffrey E. Director Jul 19 Buy 2.44 5,000 12,208 751,985 Jul 19 08:47 PM
 
DRAD Gillman Charles M Director Jul 12 Buy 2.42 5,000 12,099 726,985 Jul 16 06:31 PM
DRAD Gillman Charles M Director Jul 15 Buy 2.45 5,000 12,237 731,985 Jul 16 06:31 PM
DRAD Gillman Charles M Director Jul 16 Buy 2.45 5,000 12,240 736,985 Jul 16 06:31 PM
DRAD Eberwein Jeffrey E. Director Jul 12 Buy 2.42 5,000 12,101 726,985 Jul 16 06:30 PM
DRAD Eberwein Jeffrey E. Director Jul 15 Buy 2.45 5,000 12,239 731,985 Jul 16 06:30 PM
DRAD Eberwein Jeffrey E. Director Jul 16 Buy 2.45 5,000 12,243 736,985 Jul 16 06:30 PM
Ed ancora
 

Allegati

  • ScreenHunter_428 Aug. 11 22.31.jpg
    ScreenHunter_428 Aug. 11 22.31.jpg
    73,1 KB · Visite: 1.575
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eberwein Jeffrey E. Director Aug 14 Buy 2.49 4,800 11,955 836,785 Aug 14 08:37 PM
Eberwein Jeffrey E. Director Aug 13 Buy 2.50 5,000 12,498 831,985 Aug 14 08:37 PM
Eberwein Jeffrey E. Director Aug 12 Buy 2.46 4,000 9,824 826,985 Aug 14 08:37 PM
Eberwein Jeffrey E. Director Aug 09 Buy 2.40 5,000 12,002 822,985 Aug 09 06:48 PM
Ebe
Continua ad acquistare sempre lui ............
 
Dentro a 2,7
 
Con la nuova acquisizione fatta l anno scorso ritornano ad aumentare i ricavi mi piace dentro a 2,62
 
Nei primi giorni di giugno si sono aggiudicati un nuovo contratto da 5.2 milioni ......mi piace ...perché opera in tre settori healtcare .costruzioni. Real estate & investment.
 
Se i media non fanno panico con notizie covid, potrebbe avere un bel balzo!
Grande Mastro!
 
Come ha fatto il direttore a cedere le azioni a 7.91$?? Wtf?? :confused:

20200617_232105.jpg
 
Secondo me tra poco a questi prezzi non la vedremo più....il CEO qui spiega bene il futuro...delle 3 divisioni

------------------------------------------------------------------------------- Thank you, operator. Good morning, and thank you for joining us today for our first quarter 2020 results conference call. On the call with me today are Matt Molchan, our CEO; and David Noble, our COO and CFO. Since September of 2019, Digirad has been operating as a diversified holding company with 3 business divisions: Healthcare, Building & Construction and Real Estate & Investments. Digirad's Q1 2020 results include financial and operational data of the 2 newly created divisions, Building & Construction and Real Estate & Investments. There are no operational or financial data recorded in 2019 -- in the 2019 period for these 2 new divisions. During the first quarter of 2020, we continue to execute on our HoldCo growth strategy and value-enhancement initiatives, which we believe will increase revenue, cash flow, earnings, and ultimately, stockholder value. We expect to fund -- use our cash flow going forward to fund internal growth investments, and we'll also start looking for bolt-on acquisitions. Eventually, we'll also look to create new business divisions through the disciplined acquisition of additional operating companies that might fit well with our holding company structure. In addition, we're exploring the potential divestiture of noncore assets. To finance our expansion strategy and growth opportunities, especially for commercial projects in our Building & Construction division, on April 30, 2020, we filed a registration statement with the SEC relating to a public offering of the company's common stock for potential gross proceeds of up to $5 million. Turning to our company's growth strategy. For our Healthcare division, we'll be focusing on higher-margin segments, specifically our camera sales and mobile scanning services. In our Diagnostic services and Mobile Healthcare businesses, we continue to maintain a solid core customer base with growing prospective client pipeline. We aim to increase the utilization of our fleet and improve the density of our route-based businesses. In Diagnostic Imaging, our sales pipeline is solid and growing. We continue to focus on the sale of our unique Ergo and X-ACT cameras, and our As Needed. When Needed. And Where Needed camera rental programs. For our Building & Construction division, we're targeting the expansion of the commercial construction business at KBS. And as previously announced, KBS is currently involved in multiple discussions for several large commercial projects for the construction of multifamily housing units in the Greater Boston area. If even a few of these projects are awarded, they will require a significantly higher utilization rate for KBS' manufacturing plant in South Paris, Maine and an increased investment in working capital. Three of these projects are in advanced stages of negotiation and are expected to start production in the coming months. These 3 projects alone are expected to generate revenue of over $10 million for KBS and result in the production of nearly 250 building modules. In 2019, by way of comparison, KBS generated approximately $12 million of revenue and produced approximately 230 building modules, and that was entirely for the residential market, and we only used our South Paris, Maine plant. We believe that this plant, at full capacity, can produce 500 to 600 building modules per year. KBS has a potential sales pipeline of more than $60 million, which is greater than 1,000 building modules. So if this sales pipeline fully materialized, we could eventually reopen our currently idle plant in Oxford, Maine, which also has production capacity of 500 to 600 building modules per year. So our total manufacturing capacity is well over 1,000 building modules per year, and that compares to production of only 230 modules last year. Finally, as part of our strategy, our Real Estate & Investments division currently owns the 3 manufacturing plants in Maine that are operated by KBS. And this division completed the financing in Q1 via commercial mortgages for these 3 plants, with the proceeds used for working capital requirements for the Building & Construction division in 2020. In addition, EdgeBuilder and Glenbrook Building Supply, which are part of our Building & Construction division based in the Minneapolis area, completed a refinancing of their credit facilities in Q1
 
Ultima modifica:
anche qui sempre dentro...in attesa ..i titoli secondo me e molto buono ...c è però l incertezza mercati ..e questa impennata covid negli Usa non mi piace ....vedremo
 
anche qui sempre dentro...in attesa ..i titoli secondo me e molto buono ...c è però l incertezza mercati ..e questa impennata covid negli Usa non mi piace ....vedremo



L'impennata Covid negli Usa, dovrebbe far riflettere anche gli Stati Uniti D'Europa (se cosi' si possono chiamare)..Ma credo , nessuno sia interessato, a quello che potrebbe verificarsi tra qualche mese nel mondo intero..d'altronde l'ignoranza non ha mai avuto limiti!!!
 
Nel discorso che ha fatto Trump ad Oklahoma, ha detto che diminuiranno nei prossimi giorni i test.
Quindi a rigor di logica, mi aspetto nelle prossime settimane un calo della curva.
Credo che Trump dal momento che ha le elezioni, vorrà far sembrare che va tutto bene nei prossimi mesi.
Già il diminuire i test covid porterà (numericamente parlando) ad un calo di casi.
 
Nel discorso che ha fatto Trump ad Oklahoma, ha detto che diminuiranno nei prossimi giorni i test.
Quindi a rigor di logica, mi aspetto nelle prossime settimane un calo della curva.
Credo che Trump dal momento che ha le elezioni, vorrà far sembrare che va tutto bene nei prossimi mesi.
Già il diminuire i test covid porterà (numericamente parlando) ad un calo di casi.

Diminuire il numero di test per far sembrare minore il nr di contagiati è stupido.. se questi staranno male andranno in ospedale quindi aumenterà il nr degli ospedalizzati se non dei morti .. del resto dal parruccone pretendere strategie intelligenti è impossibile ..
 
Si gli insider sono stati molto attivi il mese scorso...un altro punto a favore..
 
Indietro